Artelo Biosciences presents important new data on ART26.12

Artelo Biosciences announced that Professor Saoirse O’Sullivan will be presenting new preclinical data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society. The conference is being held from June 4-6, 2024, in Nottingham, UK. The presentations, titled, “ART26.12, a Novel Fatty Acid-binding Protein 5 Inhibitor, shows Efficacy in Breast Cancer-Induced Bone Pain” and “The Effects of the Fatty Acid Binding Protein 5 Inhibitor ART26.12 in a Rat Model of Diabetic Neuropathy,” highlight Artelo’s Fatty Acid Binding Protein 5 inhibitor under development for painful peripheral neuropathies and various cancers. Specifically, effective doses and plasma exposures are consistent with previously published data of ART26.12 in oxaliplatin-induced peripheral neuropathy. ART26.12 represents a significant advancement in the Company’s commitment to developing innovative therapies targeting lipid signaling pathways.